The Signal
The 25bp hike landed unanimously Sept 16; 10Y yields cementing at 5.00% (highest since 2007) without triggering expected equities collapse. Two theses are pricing independently of macro chaos: defense procurement (sole-source optical moats, Pentagon backlogs, germanium tariff cliffs) and institutional crypto infrastructure (tokenization rails, Robinhood Chain stealth deployment). Clarity Act death removed regulatory overhang but hasn't killed the underlying thesis—SEC/CFTC now own the lane. Market bifurcated hard; vol is the only trade that works sideways, but winners keep running.IMPORTANT
25bp hike + Clarity death + yield meltup = defense + crypto rails outrun equities; volatility is structural, not transitional.
What's Moving
- $LPTH — G5 production-ready catalyst confirmed; $111M Pentagon backlog + 7 heat seeker programs (3 Lockheed) + germanium lock-in before Jan 1 tariff cliff insulate from rate shock. CEO hiring blitz (eng, ops, supply chain) = capital expenditure conviction. BlackRock 6.5% float = structural bid floor. Sub-$10 still accessible. (via @optimusdelta, @bussinbiotech)
- $WALLET — Robinhood Wallet branding rules confirmed stealth launch signal; logo metadata update + SEC innovation exemption announcement on same day = green light. Sept 29 hard catalyst (native token debut, gas fee shift). Institutional DTC tokenization pipeline confirmed live (BlackRock, JPM, GS, Citadel working group). Fully diluted ~$54M vs. $94B BNB comp. (via @nottellingyou73)
- $BB (QNX RTOS) — Safety-critical microkernel moat deepens as robotics TAM expands. 275M+ deployed vehicles = distribution advantage. Yield persistence = natural hedge into Q4 vol. Tape shows early-cycle setup: break above $10 confirms, break below $6 invalidates. (via @pdamodaran)
- $IOVA — Cellular immunotherapy for solid tumors (NSCLC Q4 expansion expected). UAE M&A chatter live. C-suite confidence signaling. Orphan drug data moat now recognized as AI training asset by institutional buyers. (via @crypto_condom)
- $NBIS (GPU pricing +20% Oct 1) — Demand so hot that Nebius raising rental rates before winter capex panic. Management tier-1 quality. Signals supply crunch real, not priced. (via @stocktalkweekly)
Crosscurrents
- Crypto vol compression risk — Bitcoin IV hitting rock bottom despite scorching momo; options market selling vol into steepness. When squeezed, rally could overshoot, or correction could be vicious. (via @hansolar21)
- ETH supply shock narrative — 500K ETH left exchanges in Sept alone (lowest 10Y level). Bull case hinges on criticality hitting mid/late 2028, but pace of exodus + retail FOMO could front-run timeline or exhaust demand prematurely. (via @krugman87)
- Rate meltup not fully priced — Consensus says 25bp hike priced in; long-end yield explosion (2007 highs) is not. Macro blow-ups happen fast. Defense/crypto thesis survives near-term, but leverage + duration risk real. (via @globalflows, @krugman87)
Tradecraft
BULL
Defense procurement + crypto infrastructure are pricing independently of macro; sole-source moats + tokenization = secular, not cyclical. Winners outrun equities on correction bounces.
BEAR
Yield meltup at 2007 levels = vicious intraday swings + capitulation risk. Leveraged positions will blow; consolidation likely before sustainable rally resumes.
WATCH
Sept 29 $WALLET token debut (hard catalyst). $LPTH break above $11 (production ramp). $BB weekly close above $10 (cycle confirmation). FOMC follow-up messaging (Oct, Nov).
Desk Notes
- @optimusdelta — Betting supply chain constraints (materials, minerals, components) + onshoring policy = $LPTH, $UMAC, dysprosium plays unwind into vol.
- @nottellingyou73 — Robinhood stealth Wallet launch confirmed via branding metadata + SEC innovation exemption timing. Sept 29 fully diluted token on Robinhood Chain = floodgates moment.
- @pdamodaran — $BB tape shows early cycle; agentic AI + QNX relevance wider than marketed. Still undervalued cybersecurity asset globally.
- @crypto_condom — $IOVA metastatic cancer cure (T cell immunotherapy) now recognized as AI training moat for Big Pharma M&A. Cellular oncology is secular.